REPL News and Press, Replimune Group Inc. From 08/12/22

Shares have lost half of their value since my March 2021 update. Currently, in ROTY we own 8% portfolio weighting with 20% gain. Key pivotal readouts are coming up year end (anti PD-1 failed melanoma) and Q1 2023 (CERPASS CSCC). Recent developments strengthen bullish thesis, inclu...

Gainers: Vacasa ( VCSA ) +31% . Matterport ( MTTR ) +16% . Enovix ( ENVX ) +11% . Replimune Group ( REPL ) +10% . Chicken Soup for the Soul Entertainment ( CSSE ) +6% . Losers: Sonos ( SONO ) -19% . Red Robin ...

Replimune Group press release ( NASDAQ: REPL ): FQ1 GAAP EPS of -$0.78 misses by $0.15 . As of June 30, 2022, cash, cash equivalents and short-term investments were $395.1 million. Shares -4.98% PM. For further details see: Replimune Group G...

WOBURN, Mass., June 03, 2022 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of a novel class of tumor-directed oncolytic immunotherapies, today announced Jason Rhodes, partner at Atlas Venture, has resigned from th...

WOBURN, Mass., June 02, 2022 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of a novel class of tumor-directed oncolytic immunotherapies, today announced that members of its management team will present in a firesi...

WOBURN, Mass., May 26, 2022 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL), a clinical stage biotechnology company pioneering the development of a novel class of tumor-directed oncolytic immunotherapies, today announced multiple presentations at the 2022 American Society of Clinic...

Replimune Group press release (NASDAQ:REPL): FY GAAP EPS of -$2.26 beats by $0.02. As of March 31, 2022, cash, cash equivalents and short-term investments were $395.7 million, as compared to $476.3 million as of March 31, 2021. For further details see: Replimune...

Enrollment in the CERPASS clinical trial with RP1 in cutaneous squamous cell carcinoma (CSCC) expected to be completed in mid-year 2022; top line data expected Q1 2023 Directional data from the first 75 patents with 6 months follow up from the IGNYTE clinical trial with ...

RP1 combined with Opdivo® (nivolumab) continues to demonstrate deep and durable responses in patients with melanoma and non-melanoma skin cancers (NMSC); new positive initial data in patients with anti-PD1 failed NMSC Initial data shows clinical activity with RP1 monotherap...

WOBURN, Mass., March 21, 2022 (GLOBE NEWSWIRE) -- Replimune Group Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of a novel class of tumor-directed oncolytic immunotherapies, today announced that members of its executive team and Key Opinion Leaders w...